TRACE
Trace a source
tape live—manual reviewONevidenceREQUIREDjson/trace.jsontracked horizons1D · 7D · 30D · 90Ddisclaimernot financial advicetape live—manual reviewONevidenceREQUIREDjson/trace.jsontracked horizons1D · 7D · 30D · 90Ddisclaimernot financial advice
publisheddirectional thesisLONGyoutubenot an explicit trade

LLY directional thesis

Freeberg walks through retatrutide's phase 3 data and argues it becomes Lilly's premium upsell above tirzepatide, the high-margin tier where the real money gets made. The stake is on Lilly's earnings power, not just the drug.

$965.50entry snapshot
pendingcurrent snapshot
— pendingsince mention
“Because I'm sure if I'm Lily and I'm sitting there and I'm looking at this data coming out, I'm like, my God, people will pay for this. And that starts to become sort of like the upgrade to the BMW or the Model S plat if you will.”
1:04:01claim_id mcl_30af1b847d76ff342dopen evidence ↗
Classification directional thesis

Human-reviewed public claim.

Evidence span 1:04:01

Evidence URL, source timestamp, and excerpt are attached to this permanent claim page.

Correction path available

Creators or reviewers can request reclassification, context, or entity corrections without erasing the source record.

Machine-readable claim
{
  "version": "market-claims.v1",
  "claim": {
    "id": "mcl_30af1b847d76ff342d",
    "url": "/trace/claims/mcl_30af1b847d76ff342d",
    "status": "PUBLISHED",
    "claimType": "DIRECTIONAL_THESIS",
    "direction": "LONG",
    "claimText": "Freeberg walks through retatrutide's phase 3 data and argues it becomes Lilly's premium upsell above tirzepatide, the high-margin tier where the real money gets made. The stake is on Lilly's earnings power, not just the drug.",
    "confidence": 0.72,
    "expert": {
      "slug": "allin",
      "displayName": "All-In Podcast",
      "kind": "PERSON",
      "status": "UNCLAIMED",
      "avatarUrl": "/api/avatars/acfd1290-a",
      "url": "/trace/experts/allin",
      "claimed": false
    },
    "primaryEntity": {
      "kind": "ASSET",
      "assetClass": "EQUITY",
      "symbol": "LLY",
      "name": "LLY",
      "exchange": null,
      "confidence": 0.78
    },
    "evidence": {
      "evidenceUrl": "https://youtube.com/watch?v=fpC4sbawSzQ&t=3841s",
      "sourceUrl": "https://youtube.com/watch?v=fpC4sbawSzQ",
      "timecode": "1:04:01",
      "startMs": 3841000,
      "endMs": null,
      "excerpt": "Because I'm sure if I'm Lily and I'm sitting there and I'm looking at this data coming out, I'm like, my God, people will pay for this. And that starts to become sort of like the upgrade to the BMW or the Model S plat if you will."
    },
    "performance": {
      "entryPrice": 965.5,
      "currentPrice": null,
      "returnPct": null,
      "relativePct": null,
      "method": "PASTE_AUTHOR_PRICE"
    },
    "resolutionStatus": "OPEN",
    "ambiguityNotes": null,
    "horizon": "3-12mo",
    "isExplicitTrade": false,
    "notFinancialAdvice": true,
    "disclaimer": "AISO tracks public statements, not verified portfolio positions. This is not financial advice."
  },
  "expert": {
    "slug": "allin",
    "displayName": "All-In Podcast",
    "kind": "PERSON",
    "status": "UNCLAIMED",
    "avatarUrl": "/api/avatars/acfd1290-a",
    "url": "/trace/experts/allin",
    "claimed": false
  },
  "source": {
    "platform": "YOUTUBE",
    "title": "OpenAI Misses Targets, Codex vs Claude, Elon vs Sam Trial, Big Hyperscaler Beats, Peptide Craze",
    "sourceUrl": "https://youtube.com/watch?v=fpC4sbawSzQ",
    "publishedAt": "2026-05-01T22:08:15.000Z"
  },
  "evidence": {
    "evidenceUrl": "https://youtube.com/watch?v=fpC4sbawSzQ&t=3841s",
    "sourceUrl": "https://youtube.com/watch?v=fpC4sbawSzQ",
    "timecode": "1:04:01",
    "startMs": 3841000,
    "endMs": null,
    "excerpt": "Because I'm sure if I'm Lily and I'm sitting there and I'm looking at this data coming out, I'm like, my God, people will pay for this. And that starts to become sort of like the upgrade to the BMW or the Model S plat if you will.",
    "quote": "Because I'm sure if I'm Lily and I'm sitting there and I'm looking at this data coming out, I'm like, my God, people will pay for this. And that starts to become sort of like the upgrade to the BMW or the Model S plat if you will.",
    "speaker": "David Freeberg"
  },
  "entities": [
    {
      "kind": "ASSET",
      "assetClass": "EQUITY",
      "symbol": "LLY",
      "name": "LLY",
      "exchange": null,
      "confidence": 0.78
    }
  ],
  "marketData": {
    "entry": {
      "price": 965.5,
      "currency": "USD",
      "observedAt": "2026-05-01T22:08:15.000Z",
      "method": "PASTE_AUTHOR_PRICE"
    },
    "current": null,
    "returnPct": null
  },
  "snapshots": [
    {
      "kind": "ENTRY",
      "symbol": "LLY",
      "assetClass": "EQUITY",
      "price": 965.5,
      "probability": null,
      "currency": "USD",
      "provider": "paste.trade",
      "providerSymbol": "xyz:LLY",
      "observedAt": "2026-05-01T22:08:15.000Z",
      "method": "PASTE_AUTHOR_PRICE",
      "returnPct": null,
      "relativePct": null
    }
  ]
}

AISO Market Calls classifies public statements from public sources. A classification such as long thesis, short thesis, or explicit call describes the content of the public statement and does not prove that the speaker actually entered, exited, or held a position. Market performance shown is calculated from public market data around the source publication or timestamp. It is not investment advice.